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Abstract
Objective: For patients with mild hepatitis A virus (HAV) infection, this study compared estimates
of total costs associated with managing cases under a policy of mandatory hospitalization in the
Republic of Kazakhstan and estimates of total costs associated with managing cases in outpatient
settings. Costs were estimated both from the perspective of the Ministry of Health and from a
broader societal perspective.
Methods: Data were collected by using a standardized structured questionnaire. For cases of mild
HAV infection, medical records were obtained from 200 patients managed by hospitalization and
from 251 patients managed in an outpatient setting. Personal interviews were also conducted to
collect information on productivity losses and out-of-pocket expenses.
Results: Nationally, we estimated about 21,600 cases of mild HAV infection annually. The mean
annual treatment costs  in hospital for mild HAV infection was estimated at US$3.39 million (2001
US$) (95% confidence interval [CI] = [US$3.26 million – US$3.52 million]). The total annual mild
HAV infection cost to the society, including direct medical and nonmedical costs and productivity
losses due to 721,440 lost work days, was estimated at US$6.26 million (95% CI [US$6.05 million
– US$6.47 million]). In sensitivity analyses, the total annual cost of mild HAV infection ranged from
US$4.37 million to US$24.66 million. The survey results showed that a relatively minor change in
the current policy of mandatory hospitalization could result in an estimated total annual savings of
US$4.62 million (2001 US$) in Kazakhstan.
Conclusion: Adoption of an outpatient management policy for cases of mild HAV infection would
generate substantial cost savings to the Ministry of Health and society.
Background
The average annual incidence rate of hepatitis A virus
(HAV) infection varies significantly worldwide ranging
from 9.1 per 100,000 in the United States and Europe to
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500 per 100,000 in the Central Asian Republics [1,2].
According to the latest available data, the incidence of
HAV infection remains as high as 150 cases per 100,000
population in the Central Asian Republics and Kaza-
khstan in 2001 [3,4]. Although HAV infection incidence
has decreased slightly compared to the figures for the last
decade, the persistence of high incidence in Kazakhstan is
mainly due to problems related to poor supplies of good-
quality drinking water, sanitation and hygiene practices
[1,5,6]. It has been documented that the incidence of HAV
infection is closely linked to poor socio-economic living
conditions [3].
HAV infection is usually a mild illness, but can be severe
if it occurs concurrently with other diseases or comorbid
conditions [7-10]. In Britain, and North America, a
patient with HAV infection is hospitalized only if (a) (s)he
is too sick with diarrhea, nausea, and vomiting to be man-
aged appropriately with antiemetics and oral rehydration
at home, (b) (s)he has hepatic and/or renal failure (some-
times seen with HAV-infection in persons with underlying
alcoholic liver disease or with chronic hepatitis caused by
other viral agents) [11], or (c) (s)he has a clinical presen-
tation that is truly anomalous (e.g., meningoencephalitis
has been reported in association with HAV infection but
is exceedingly rare [12]). However, in many republics of
the former Soviet Union, HAV infection has been a cause
for routine hospitalization, as mandated in administrative
directives. The premise on which many such patients are
hospitalized should be reconsidered because relatively
few patients with HAV infection become seriously ill, no
treatment to influence the underlying course of the dis-
ease exists, and neither admission to hospital nor isola-
tion from others in the home lessens the spread of the
infection [13].
Because HAV infection is neither a severe illness nor one
with important sequelae, it has been observed that the
rates of infection of family members of patients with mild
HAV managed at home or in hospital were similar [13-
15]. Previous studies using data from the region reported
that the hospitalization of patients after the appearance of
jaundice was unjustified, and that the quality of treatment
between inpatient and outpatient settings would be simi-
lar [13,14]. However, in severe cases (<10% of HAV infec-
tions), patients are more likely to be managed in a
hospital and to receive more intensive treatment, includ-
ing ultrasound and computerized tomography exams, as
well as liver biopsies [7,8,10]. In such cases, the assump-
tion of similar quality of inpatient and outpatient treat-
ment does not hold.
Using data gathered from patients with mild HAV infec-
tion in Almaty, Kazakhstan, we conducted a cost-compar-
ison analysis of the policy of mandatory hospitalization
and an alternative policy of outpatient management for
patients with mild HAV infection. The purposes of this
study were (a) to determine the mean treatment costs
associated with managing cases of mild HAV infection in
an inpatient setting under a policy of mandatory hospital-
ization, (b) to compare those costs with costs of treating
patients with mild HAV infection using outpatient man-
agement, assuming a similar quality of treatment under
inpatient and outpatient conditions, and (c) to determine
total direct medical and nonmedical costs as well as pro-
ductivity losses associated with mild HAV infection and
then compare these costs both from the perspective of the
resource-allocating authority (i.e., the Ministry of Health)
and from a broader societal perspective.
Materials and methods
Data sources
Data were collected using survey questionnaires that
involved interviews with patients and medical practition-
ers between November 2000 and February 2001. Informa-
tion was collected on patient's age, sex, principal
diagnosis, duration of illness, use of services, and cost
data. Patients were interviewed to collect information
regarding out-of-pocket and direct nonmedical expenses,
such as expenses paid for transportation to outpatient
clinics and indirect costs associated with the number of
days absent from work. Interviews with medical person-
nel and hospital administrators were conducted to deter-
mine the costs and quantify the amount of health and
nonhealth staff time spent per day in caring for patients
with mild HAV infection.
A sample size of 451 subjects (200 inpatients and 251 out-
patients) was used to conduct a cost-comparison analysis.
We enrolled patients presenting to either of two hospitals
in Almaty, Kazakhstan, in a geographical area where man-
datory hospitalization for mild HAV infection was still
practiced. We also enrolled patients in 19 outpatient clin-
ics in geographical areas where mandatory hospitalization
was no longer practiced. Patients selected for the study
included members of both sexes, all age groups, and var-
ied in ethnicity.
Case definition
A case of mild HAV infection was defined as a clinical
presentation with manifestations of acute hepatitis and
serologic confirmation of HAV infection in a person who
reported to one of the selected hospitals or outpatient
clinic sites. The clinical manifestations of HAV infection
included sudden onset of fever, anorexia, fatigue, and/or
abdominal discomfort followed within a few days by
jaundice and hepatomegaly [16-18]. Serologic confirma-
tion of mild HAV infection was determined by elevated
alanine serum transferase (AST) not in excess of 5 timesCost Effectiveness and Resource Allocation 2005, 3:4 http://www.resource-allocation.com/content/3/1/4
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the upper limit of normal of the reference value, and by
presence of detectable IgM anti-HAV
Criteria for inclusion in this analysis were (a) having mild
HAV infection as a primary or sole diagnosis confirmed by
laboratory; (b) being between 1 and 65 years of age and
being either hospitalized or managed at one of the study
sites by a health care worker during the study period; and
(c) providing voluntarily signed consent that included
permission to review medical records. Persons who had
multiple concurrent diseases or comorbid conditions and
those who had not been diagnosed and tested positive for
mild HAV infection more than 30 days before the study
period were excluded from the study.
Cost description
Costs for direct medical and non-medical services pro-
vided for patients with mild HAV infection were calcu-
lated based on interviews with medical providers, hospital
administrators, health officials and patients. Units of
direct medical services recorded included the number of
days spent in hospital, health staff time allocated to treat-
ment, and costs for those services specifically identified as
part of the management of patients with mild HAV infec-
tion in hospital and outpatient clinics. Time spent by
health care personnel was obtained based on reviews of
medical records. Costs were based on estimates of costs
for time spent by hospital- or clinic-personnel per day in
caring for patients with mild HAV infection: in hospital,
physicians spent approximately 54 minutes (min.),
nurses approximately 89 min., and nonhealth staff about
40 min.; in the outpatient clinics, physicians spent
approximately 26.4 min., nurses approximately 18 min.,
and nonhealth staff a negligible amount of time. In this
analysis, we are considering only the base salary for the
health care personnel; physicians are paid US$15.84 per
8-hour workday, US$4.8 per day for nurses, and US$2.4
per day for nonhealth staff obtained from the budget of
each health facility and based on the national contract for
health personnel. Although physicians earn more than
their base salary through various bonus payments and
through informal payments from patients, consistent esti-
mates of these payments could not be captured and were
not included in this analysis [6,19,20]. Since an estimated
80% to 90% of physician income is obtained informally
[20], it is difficult to track the flow of incomes for doctors,
and we were able to use only the base salary for our
estimates.
The cost per patient-hospital day included the costs of
purchase and repair of medical equipment and buildings,
administrative and operational costs in the hospitals allo-
cated to the treatment of mild HAV patients. To cover the
full capital and recurrent cost, cost per patient-hospital
day was determined based on average national estimates
provided by hospital administrators [21-23]. Although
hospital costs cover capital and recurrent costs such as the
cost of building and medical equipment, laboratory serv-
ices, health and nonhealth personnel, and hospital
administrative costs, we estimated separately the costs for
laboratory and personnel services for managing patients
in hospital based on medical records and interviews with
medical practitioners. Costs for hospital meals and pre-
scription drugs were obtained based on patient self-
reported out-of-pocket expenses. The cost of hospital
meals was estimated for the respective number of inpa-
tient hospital days. The number of hospital days was
determined based on patient medical records. Because all
patients paid for hospital meals and prescription drug
charges where incurred, we calculated the cost of hospital
meals and prescription drugs separately.
Total treatment costs were calculated as the sum of direct
medical and non-medical costs which included hospital
costs, costs for time spent with patients by physicians,
nurses, and other staff, laboratory and prescription drug
costs, as well as non-medical costs such as hospital meals
and transport. Because there are no long-term sequelae of
mild HAV infection [7,10], no home care was needed for
such patients; therefore, the cost of home care was not cal-
culated. Productivity losses were calculated as indirect
costs associated with lost workdays due to illnesses of
HAV infection. The number of lost workdays were deter-
mined based on self-reports of missed work. The exchange
rate used was US$1 = 148 Kazakhstan Tenge (KZT), a rate
that has not varied more than 15% since January 2001. As
of May 5, 2005, the exchange rate was US$1 = 131 KZT.
Treatment outcome
Having measured the direct medical and nonmedical
costs, as well as productivity losses of managing mild HAV
infection, we defined effective treatment or management
for a mild HAV infection as an episode of care (which
included all services provided) that led to a complete
recovery. As has been observed epidemiologically else-
where, we assumed that the rates of infection of family
members of patients with mild HAV infection managed at
home or in hospital were similar [13,15].
Statistical analyses
We completed our analyses in five stages: First, we esti-
mated the mean annual treatment cost per case of mild
HAV infection when managed in inpatient and outpatient
settings. Using SAS statistical programs, comparison
between inpatient and outpatient groups were made using
PROC TTEST of the null hypothesis of equal group vari-
ances, and we determined the difference in mean treat-
ment cost per case using t tests of differences in means.
The confidence interval (CI) for the difference betweenCost Effectiveness and Resource Allocation 2005, 3:4 http://www.resource-allocation.com/content/3/1/4
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two sample means was obtained using a "pooled" esti-
mate of the standard deviation [24].
Second, we stratified the samples by four different age
groups, given significant differences in mean age between
the two groups. We categorized patients into four age
groups: ≤  18, 19 – 26, 27 – 34, and ≥  35 years to estimate
the mean annual treatment cost per case of mild HAV
infection by age group. We used PROC GLM to conduct
one-way analysis of variance (ANOVA) using Bonferroni t
tests of pair of means within age groups to test the null
hypothesis of equality of the group means among differ-
ent age groups.
Third, we estimated the number of lost workdays for both
inpatient and outpatient group. We calculated the produc-
tivity losses by multiplying the number of lost workdays
by employed patients aged 18 – 64 years or by adult par-
ents or guardians of children with mild HAV infection,
and by daily urban wage rates. In this analysis, we did not
consider replacement costs for unemployed patients.
Fourth, we estimated the total annual cost of mild HAV
infection as the sum of the annual treatment costs consist-
ing of direct medical and nonmedical costs as well as pro-
ductivity losses resulting from lost workdays.
Finally, we conducted sensitivity analyses to determine
which parameters exert the greatest influence on the
results of this analysis and establish the range of total
annual cost of mild HAV infection. A p-value ≤  0.05 was
considered to be statistically significant. Epi Info software
[25] was used for data entry. Data from questionnaire
forms were entered twice into a computer database to
reduce the chances of data-entry errors and were analyzed
using SAS statistical programs [26].
Results
Table 1 presents sociodemographic characteristics of the
inpatient and outpatient groups. The mean age of the
inpatient group was 22 years; the mean age of the outpa-
tient group was 12 years. The inpatient group reported a
higher annual household income of US$898.2 (2001
US$) compared with US$502.3 for the outpatient group.
Several other comparisons reflected disparities in age of
the two sample groups: 26.5% of the inpatient group was
employed, compared with 6.7% of the outpatient group;
21% of the inpatient group were married, compared with
8.9% of the outpatient group; 32% of the inpatient group
smoked cigarettes, compared with 9.9% of the outpatient
group. The average wage rate per patient in urban areas
was 14,617 KZT (US$98.76) per month compared to
5000 KZT (US$33.78) per patient in rural areas. There
were 27.21 lost workdays for employed inpatients and
6.19 lost workdays for family members caring for minor
patients in hospital; employed outpatients had an average
of 15.73 lost workdays (lost workdays: 33.40 vs. 15.73).
The average length of hospital stay for a patient with mild
HAV infection was 9.7 days, compared with 3.4 visits per
patient in the outpatient group.
Table 2 presents the mean treatment costs per patient with
mild HAV infection in inpatient and outpatient settings.
The mean total direct medical and nonmedical cost of
managing mild HAV infection was estimated at US$157.4
(2001 US$) per inpatient (95% CI = US$151 – 163), com-
pared with US$22.5 per outpatient (95% CI = US$21 –
23). The hospital costs (US$81) were calculated by taking
the product of the average number of hospital days (9.7
days) and the cost per HAV patient-hospital day (US$8.4)
obtained from the survey. Of the US$81 of hospital costs,
as much as 40% (US$32) of the hospital costs was allo-
cated to the costs for the purchase and repair of medical
equipment and buildings and 60% (US$49) was spent on
recurrent hospital administrative and operational costs
including overhead and utilities. Laboratory costs
accounted for 6.9% (US$11.0) of the mean treatment
costs for inpatients compared with 35.6% (US$8.0) of
those costs for outpatients. We estimated that about 19%
(US$30) of the mean treatment costs were allocated to
hospital meals.
From the perspective of the Ministry of Health, the mean
direct medical costs of managing mild HAV infection was
estimated at US$127.4 per patient in hospital, compared
with US$18.5 in an outpatient setting. From the societal
perspective, the mean total cost of direct medical and non-
medical services as well as of productivity losses was esti-
mated at US$308.3 per patient in hospital compared with
US$94.0 per patient in an outpatient setting. Of the
US$157.4 total for direct medical and nonmedical serv-
ices, a patient in hospital paid approximately US$36.4 out
of pocket costs for drugs and hospital meals, compared
with US$9.9 for such costs paid by a patient in an outpa-
tient setting.
Results from the PROC TTEST indicated that the differ-
ence between the mean treatment costs for management
of mild HAV infection among the inpatient and outpa-
tient groups was US$134.6 (2001 US$), 95% CI = (US$
128.0 – 140.0) and statistically significant at (p ≤  0.0001).
When we controlled for the effect of age on medical cost
by stratifying the samples by age group, we found that the
mean treatment costs in the outpatient setting was still
considerably lower than those in the inpatient setting. For
example, the mean treatment costs of managing cases of
mild HAV infection for outpatients aged 19 to 26 years
was estimated at 13.9% of that for the inpatients of the
same age. The one-way ANOVA analysis indicated that the
mean treatment costs per inpatient decreased as ageCost Effectiveness and Resource Allocation 2005, 3:4 http://www.resource-allocation.com/content/3/1/4
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increased (Figure 1). The mean treatment cost per inpa-
tient for the age group ≥  35 years was estimated at US$144
compared with US$163 for the age group ≤  18 years (F-
value = 1.40; p = 0.25). Results from this analysis indi-
cated that although there were differences in population
means among different age groups, these differences were
not statistically significant. We also noted that the mean
treatment cost per outpatient in the age group ≥  35 years
was estimated at US$28 versus US$22 for the age group ≤
18 years (F-value = 2.05; p = 0.10). Again, results from this
analysis indicated that although there were differences in
population means, these differences were not statistically
significant. Mean treatment costs as well as productivity
losses per outpatient increase slightly as age increases
(Table 3).
Nationally, we estimated about 21,600 cases of mild HAV
infection occurred during 2001. Of these cases, an esti-
mated 19,008 employed patients with HAV infection
would report lost workdays due to illness considering the
12% unemployment rate in Kazakhstan [6]. Assuming no
replacement costs of unemployed sick workers, we calcu-
lated the productivity losses by multiplying the average
lost wages of US$150.9 per inpatient by the cases of
employed inpatients. We estimated the productivity
losses at US$2.87 million (95% CI = US$2.79 million –
US$2.95 million). Using 21,600 cases of mild HAV infec-
tion, an average of 9.7 hospital days and 33.4 lost work-
days per inpatient, we calculated a total of 209,520
hospital days and 721,440 lost workdays. Annual mild
HAV infection treatment costs for inpatients were esti-
mated at US$3.39 million (95% CI = US$3.26 million –
Table 1: Sociodemographic characteristics of patients with mild HAV infection, Almaty, Kazakhstan, 2001
Variables All patients (n = 451) Inpatients (n = 200) Outpatients (n = 251)
Gender (%)
Male 50.9 50.0 51.4
Female 49.1 50.0 48.6
Marital status (%)
Married 17.8 21.0 8.9
Unmarried 85.2 79.0 91.1
Education level (%)
Never attended or kindergarten 13.2 0.5 23.4
School 1–8 years 55.8 72.0 42.7
Grades 9–11 years 16.3 27.5 17.3
High school graduate 1.1 - 2.0
College 1–3 years or graduate 13.6 - 14.5
Ethnicity (%)
Kazakhs 40.6 36.0 44.2
Russians 49.2 54.5 45.0
Uzbek 2.4 2.0 2.8
Others 7.8 7.5 8.0
Employment status (%)
Employed 16.4 26.5 6.7
Unemployed 83.6 73.5 93.3
Tobacco use (%)
Smoker 20.3 32.0 9.9
Nonsmoker 79.7 68.0 90.1
Urban status (%)
Urban 99.8 100.0 99.6
Rural 0.2 - 0.4
Home ownership (%)
Owned 98.2 99.5 97.2
Rented 1.8 0.5 2.8
Age group (%)
≤  18 66.3 37.5 89.2
19 – 26 22.6 42.5 6.8
27 – 34 6.7 12.5 2.0
≥  35 4.4 7.5 2.0
Mean Age (years) (SE) ¶ 17 (0.41) 22 (0.49) 12 (0.43)
Mean household income (US$) (SE)¶ 886.6 (60.03) 898.2 (61.65) 502.3 (28.38)
¶ Standard error (SE) are values in parenthesis.Cost Effectiveness and Resource Allocation 2005, 3:4 http://www.resource-allocation.com/content/3/1/4
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US$3.52 million). These costs could be lowered by man-
aging patients with mild HAV infection in an outpatient
setting for as low as US$486,000 (95% CI = US$453,600
– US$496,800).
From the societal perspective, the annual total cost of mild
HAV infection for patients treated in hospital was
estimated at US$6.26 million, 95% CI = (US$6.05 –
US$6.47). The treatment costs represent 51% of the total
costs whereas productivity losses account for 49% of the
total costs. The total cost of managing mild HAV infection
in an outpatient was estimated at US$1.85 million, 95%
CI= (US$1.72 – US$1.95). The annual total cost of mild
HAV infection could be reduced by almost 70% from
US$6.26 million to US$1.85 million by encouraging
patients with mild HAV infection to be treated in outpa-
tient rather than in inpatient settings. Using an average
saving (US$214) per inpatient and 21,600 cases of mild
HAV infection, the potential savings at the national level
from changing the treatment setting from inpatient to
outpatient would be about US$4.62 million (2001 US$)
per year.
Discussion
Our findings suggest that the mean treatment costs per
patient managed in hospital were almost seven times the
costs per patient in an outpatient setting. Our results were
consistent with previous reports that inpatient care is
more expensive than outpatient care settings [6]. Even
though no other study has directly estimated the costs of
mild HAV infection in Kazakhstan, we observed how
expensive the inpatient setting in the region was, relative
to the outpatient setting. Health systems in the Central
Asian Republics, including Kazakhstan, have not been
designed and managed with attention to the criteria of
technical efficiency (the production of a defined set of serv-
ices at the lowest cost within the health system; also
known as operational efficiency) or allocative efficiency
(the distribution of resources across varied range of serv-
ices in an optimum manner). These health systems have
tended to overinvest services provided in inpatient set-
tings; hospitals utilize approximately 75% of the Kaza-
khstan health budget compared to 10% of the budget for
outpatient care [6]. Many disease entities managed with
outpatient treatments in European Union countries
(including viral hepatitis and tuberculosis) are managed
on an inpatient basis in Kazakhstan [6]. In order to pro-
vide optimal care within the budget limits imposed by the
allocation of hospital resources to various emerging infec-
tious diseases like human immunodeficiency virus (HIV)
infection, health authorities should consider choosing
health care practices known to be beneficial on the basis
of evidence of cost-effectiveness [27]. Inefficiency in the
use of public funds has resulted in the increasing practice
of informal or 'under-the-table' payments in the health
system [6].
Informal out-of-pocket expenses are increasingly required
due to declining funds for the health sector. In the late
1990s, a 65% reduction in government revenues resulted
in insufficient health sector funding that led to delays in
wage payments and shortage of medical supplies [20].
Although the benefit package in Kazakhstan has covered
inpatient drug costs, many hospitals in practice cannot
Table 2: Mean treatment costs of managing cases of mild HAV infection for inpatient and outpatient settings, Almaty, Kazakhstan 
(2001 US$)
Inpatient Outpatient
Cost items (US$) Mean SE† 95% CI‡ Mean SE† 95% CI‡
Hospital cost 81.0 1.78 (89.0, 96.0) - - -
Physicians' time 18.0 0.49 (17.0, 19.0) 3.0 0.08 (2.80, 3.20)
Nurses' time 9.0 0.17 (8.7, 9.30) 1.6 0.07 (1.46, 1.70)
Non-health staff 2.0 0.04 (1.92, 2.10) - - -
Laboratory 11.0 0.35 (10.0, 12.0) 8.0 0.11 (7.8, 8.2)
Prescription drugs 6.4 0.21 (6.19, 7.01) 5.9 0.33 (5.25, 6.55)
Hospital meals 30.0 0.57 (29.0, 31.0) - - -
Transport - - - 4.0 0.20 (3.60, 4.40)
Total inpatient/outpatient 157.4 3.04 (151.0, 163.0) 22.5 0.42 (21.0, 23.0)
Productivity losses¶ 150.9 2.12 (146.7,155.1) 71.5 4.75 (66.8, 76.3)
Total societal cost§ 308.3 4.90 (298.7, 317.9) 94.0 4.28 (85.6, 102.4)
Note: Data may add exactly due to rounding
†Standard error (SE)
‡95% Confidence interval (95% CI)
¶Productivity losses calculated based on the number of lost workdays reported and average urban wage rate.
§ Total societal costs include treatment costs and productivity lossesCost Effectiveness and Resource Allocation 2005, 3:4 http://www.resource-allocation.com/content/3/1/4
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Mean treatment costs per mild HAV inpatient by age group Figure 1
Mean treatment costs per mild HAV inpatient by age group
Table 3: Mean, median total cost and standard error of managing mild HAV infection, by age group and treatment setting (inpatient 
vs. outpatient), Almaty, Kazakhstan (2001 US$)
Total cost* per inpatient Total cost* per outpatient
Age (years) n§ Mean (SE†) Median cost n§ Mean (SE†)M e d i a n  c o s t
≤  18 75 320 (32.42) 319 224 92 (8.64) 97
19 – 26 85 303 (6.72) 304 17 96 (4.75) 97
27 – 34 25 302 (11.25) 304 5 111 (11.60) 111
≥  35 15 290 (12.88) 292 5 93 (12.95) 101
All 200 308.3 (4.90) 304 251 94 (4.28) 98
* Note the total cost includes the treatment costs as well as productivity losses
§ Sample size
†Standard error (SE)
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afford to supply them. Therefore, patients often pay for
food and drugs while they are in hospital [6]. These
expenditures are informal payments that patients are
asked to pay out-of-pocket. Our results were consistent
with the findings of Ensor and Savelyeva, that estimates of
patient per capita payment for prescription drugs in hos-
pital range between US$ 8.5 and US$10.4 [20,28,29]. In
Kazakhstan, private practice has been permitted since
1991, and more physicians are becoming semi-autono-
mous practitioners in group practices funded through a
patient capitation fund. Many local health authorities per-
mit health facilities to establish charge departments in
order to obtain additional revenue [20]. User charges for
medical services by public sector health organizations
were legalized in 1995. Now, health care facilities charge
for services, and as a result, outpatients make official co-
payments for the treatment [6].
In addition to these official charges, recent surveys indi-
cated that informal payments to health care practitioners
continue to exist, ranging from US$5 for consultations to
thousands for an operation [6,20,30,31]. In this paper,
estimates of out-of-pocket expenses were obtained by
interviewing patients. Higher costs in inpatient settings
may reflect unnecessary use of hospital resources. Other
factors that contributed to higher costs in inpatient serv-
ices may be due to the decrease in government revenues
that used to subsidize the hospital services, low official
salaries of health care staff, and growth in private health
care services [6]. Because of these latter factors, medical
practitioners seek augmentation of income via the infor-
mal payments [20]. User fees for those who can afford
them or cost-sharing strategies could address the prob-
lems of under-funding in health systems, stabilize these
informal payments, and free up public funds. By balanc-
ing the mix of resources and increasing the proportion of
spending on services managed in outpatient settings, Min-
istries of Health in Central Asia might be able to achieve
optimal allocation of resources in the health care system.
Our findings may be conservative for three reasons. First,
in estimating mean treatment costs, we did not consider
informal payments to health care staff. Second, our esti-
mates of productivity losses were based on 264 working
days per year (22 working days per month) and did not
include the value of housekeeping productivity losses.
Third, we used lower estimates of the number of patients
with mild HAV as 150 per 100,000; the upper estimates of
this figure could be as high as 500 per 100,000.
This study has some limitations. First, we did not evaluate
post-treatment health outcomes after hospital discharge,
including completion of outpatient visits. However, there
is a wealth of literature that has demonstrated a lack of
long-term health outcome differences between persons
restricted to bedrest or institutionalized and persons
forced to exercise or allowed to engage in activities ad libi-
tum when symptomatic with acute HAV infection [32,33].
Second, because of lack of reliable data, we were unable to
obtain the capital costs of outpatient facilities including
the cost of space, maintenance for facility and medical
equipment, overhead, and utilities associated with the
treatment of mild HAV infection; therefore, our cost esti-
mates for the outpatient might be biased toward the lower
end. Despite these potential concerns, these limitations
would not invalidate the findings of this study.
In sensitivity analyses, we varied some parameters to
establish the range of annual cost estimates of mild HAV
infection. We observed that annual cost estimates are sen-
sitive to the following four variables: value of medical
services, number of lost workdays, average wage rates, and
incidence of HAV infection cases. In these analyses, the
annual cost estimates of mild HAV infection varied from
US$4.37 to US$24.66 million (Table 4). Considering
patients with multiple concurrent diseases or patients
diagnosed with severe HAV, cost of medical services can
vary significantly.
Table 4: Total annual cost estimates of mild HAV infection for inpatients in sensitivity analysis, Kazakhstan, (2001 US$) in millions
Analysis Treatment cost Productivity losses Total cost
Base case assumption 3.39 2.87 6.26
Value of medical services † 4.89 2.87 7.76
Rural wage rate (KZT 5000 per month) § 3.39 0.98 4.37
Greater adjustment of hepatitis A under-reporting¶ 12.59 12.07 24.66
Note the total cost includes the treatment costs as well as productivity losses
†an estimated informal payment is included. When 80–90% informal payment is taken into account, the treatment costs were estimated at 
US$226.2 per inpatient.
§ reported wage rate based on the survey results
¶ annual incidence of hepatitis A as high as 500 per 100,000 (reported in the Central Asia Republics in 1998)Cost Effectiveness and Resource Allocation 2005, 3:4 http://www.resource-allocation.com/content/3/1/4
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Future research should consider conducting cost-effective-
ness analyses (CEA) taking into account the quality of
post-treatment outcomes rather than assuming similar
treatment outcomes among inpatients and outpatients. In
conducting these analyses, researchers should consider
two possible scenarios: (a) the treatment outcome for the
inpatient setting is better than that for the outpatient set-
ting (in this case, the inpatient setting is more costly and
more effective than the outpatient setting, so an incre-
mental cost-effectiveness analysis should be conducted);
and (b) the treatment outcome for the outpatient setting
is as good as or better than that for the inpatient setting
(thus, because the cost of managing mild HAV infection
for outpatients is lower than for inpatients, cost savings
should be calculated).
Conclusion
From a societal perspective, the annual total treatment
costs and productivity losses associated with mild HAV
infection ranged from US$6.05 million to US$6.47 mil-
lion for inpatients compared to a range of US$1.72 mil-
lion to US$1.95 million for patients in the outpatient
setting. The results of this study show that compliance
with a change in the policy of hospitalization for patients
with mild HAV infection could produce savings of
US$4.62 million at the national level in Kazakhstan.
Appendix
Before beginning this study, we obtained institutional
review board (IRB) approval (Protocol No. 2708) from
the Centers for Disease Control and Prevention (CDC)
Assurances-Human Subjects Office. In addition to CDC
IRB approval, we also obtained an approval letter from
the Ethics Committee Review from the Ministry of Health
in Kazakhstan. Prior to administering questionnaires and
interviews with patients, we explained the purposes of the
study and obtained informed consent forms signed by all
adult patients with mild HAV infection. Parents or guard-
ians of all child participants with mild HAV infection
under 18 years of age signed the informed consent forms
for children. This study was conducted in collaboration
with the Data for Decision Making and Policy Branch of
the Division of International Health (DIH), Epidemiol-
ogy Program Office (EPO) of CDC, the CDC Central
Asian Regional Office (CDC/CAR), and the Almaty City
Sanitary and Epidemiological Stations of the Ministry of
Health in Almaty, Kazakhstan.
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